- Company
- 12 Korean biosimilars globally approved in 3 months
- by Chon, Seung-Hyun Mar 12, 2025 05:56am
- Domestic pharma and biotech companies have achieved 12 biosimilar approvals in the U.S. and Europe this year. Celltrion and Samsung Bioepis have surpassed last year's record of 11 approvals in three months due to their rapid global expansion. Together, Celltrion and Samsung Bioepis have received over 20 biosimilar approvals in Europe and the Uni
- Company
- Besremi demonstrates effects in polycythemia vera
- by Whang, byung-woo Mar 11, 2025 05:54am
- "In polycythemia vera, 10&8211;20% of patients develop resistance or intolerance to hydroxyurea treatment. Since no other treatment option is available, reimbursement for the new treatment option must be considered." Although the average survival for polycythemia vera is around 14.1 years, typically considered a comparatively lower mortality
- Company
- Celltrion’s Xolair biosimilar Omlyclo is approved in the US
- by Chon, Seung-Hyun Mar 11, 2025 05:54am
- Celltrion announced on the 10th that ‘Omlyclo,’ its biosimilar version of ‘Xolair’ has was approved by the US Food and Drug Administration (FDA). Xolair is an antibody biologic used for allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic spontaneous urticaria (CSU). Xolair posted global sales of approximate
- Company
- AbbVie’s Rinvoq to benefit most from changes in KOR
- by Whang, byung-woo Mar 10, 2025 06:05am
- Expansion has been growing on the expansion of related prescription markets with the government approving reimbursement for switching between atopic dermatitis treatments, which has been in high demand in the field. The industry expects an increased number of treatment options and an expanded scope of reimbursement to enable more effective tr
- Company
- Greenlight for reimbursement of ' Tepmetko'
- by Eo, Yun-Ho Mar 10, 2025 05:51am
- The MET-targeted anticancer drug 'Tepmetko' has gained the greenlight to the insurance reimbursement coverage. According to industry sources, Merck Korea has agreed to the drug pricing negotiations with the National Health Insurance Service (NHIS) for its Tepmetko (tepotinib), a treatment for patients with topically advanced or metastati
- Company
- The cardiomyopathy drug 'Vyndamax' is reimbursed
- by Whang, byung-woo Mar 10, 2025 05:50am
- 'Vyndamax,' a new drug for the treatment of transthyretin amyloid cardiomyopathy, has recently been added to the insurance reimbursement list after five attempts. Three years have passed since the company initially applied for the listing. Consequently, the prescription of Pfizer Korea's Vyndamax (tafamidis 61 mg) is now covered with reimb
- Company
- Reimb approval JAKi switching can change RA treatment in KOR
- by Son, Hyung Min Mar 7, 2025 05:56am
- “The realistic goal for treating rheumatoid arthritis is remission, not cure. With various treatment options introduced for the disease, patients can expect good results if they start treatment by administering the right treatment for them. In particular, since switching is now allowed for oral treatment options like JAK inhibitors, this ma
- Company
- Roche adds expertise through leadership appointments
- by Whang, byung-woo Mar 7, 2025 05:56am
- Roche Korea is strengthening its leadership by appointing new leads to its Oncology and Hematology cluster and Specialty Medicines cluster. The company announced on the 5th that it has appointed Jinyoung Jeong as the new head of the Oncology·Hematology Cluster and Hyun-mi Kim as the new head of the Specialty Medicines Cluster. By appo
- Company
- SK Chemical signs a joint sales agreement with Viatris
- by Lee, Seok-Jun Mar 6, 2025 05:58am
- SK Chemicals, which developed the first natural drug for osteoarthritis in Korea, ‘Joins Tab,’ has secured additional pain medications for its portfolio. SK Chemical (CEO Jae-Hyun Ahn) announced on the 5th that it has signed a distribution and sales agreement with Viatris Korea for △Lyrica, △ Neurontin, and △ Celebrex. Under the
- Company
- Vyndamax is reimbursed for ATTR-CM in Korea
- by Whang, byung-woo Mar 6, 2025 05:58am
- Pfizer Korea announced on the 5th that its Vyndamax (tafamidis), a treatment for wild-type or hereditary transthyretin amyloidosis cardiomyopathy (ATTR-CM), has been granted reimbursement by Korea’s National Health Insurance. ATTR-CM is a progressive rare disease in which the naturally circulating transport protein in the blood, transthy
